Surging growth of its Cymbalta depression treatment helped Eli Lilly & Co. (NYSE: LLY) beat Wall St.’s earnings expectations. But generic rivals to Plavix, other drugs hurt Bristol-Myers Squibb Co. (NYSE: BMY) second-quarter results.
Eli Lilly said it earned $924 million, or $0.83 per share, in the second quarter. That was down from $1.2 billion, or $1.07 per share in the year-earlier period. Analysts polled by Thomson Reuters expected $0.77 per share. Global sales of $5.6 billion were in line with consensus estimates.
Eli Lilly said it now expects full-year 2012 earnings of $3.30 to $3.40 per share, excluding special items. The previous forecast called for EPS of $3.15 to $3.30. The drugmaker raised its outlook due to the favorable impact of a stronger dollar.
Bristol-Myers said its net income in the quarter plunged 28% to $645 million, or $0.38 cents per share. Adjusted EPS of $0.48 was in line with analysts’ expectations. Total revenue fell year-over-year by 18% to $4.44 billion, which also more-or-less matched consensus estimates.
Bristol-Myers said it now expects 2012 earnings per share of $1.78 to $1.88, although its forecast excluding one-time items remains at $1.90 to $2.00 per share.
Eli Lilly is up about 1.2% in premarket trading to $42.50, in a 52-week range of $33.75 to $44.67. Bristol-Myers closed Tuesday at $34.73, in a 52-week range of $25.69 to $36.34. The mean price target on Bristol-Myers is less than 2% higher than that closing price. Eli Lilly’s current price is higher than the mean price target on shares.
Take Charge of Your Retirement In Just A Few Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
- Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
- Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
- Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.